Stock Financial Ratios, Dividends, Split History

CQP / Cheniere Energy Partners, LP financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price36.29
Volume389,600.00
Market Cap ($M)8,879.43
Enterprise Value ($M)36,924.43
Book Value ($M)-1,397.00
Book Value / Share-5.73
Price / Book-6.36
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 237,600,000
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Weighted Average Number Of Diluted Shares Outstanding 233,100,000
Weighted Average Number Of Shares Outstanding Basic 233,100,000
Common Shares Outstanding 237,656,695
Scoring Models
Piotroski F-Score7.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)-0.40
Balance Sheet (mrq) ($M)
Assets28,341.00
Liabilities29,738.00
Quick Ratio3.51
Current Ratio3.65
Income Statement (mra) ($M)
Revenues5,601,000,000.00
Oil And Gas Sales Revenue5,317,000,000.00
Sales Revenue Services Net260,000,000.00
Other Sales Revenue Net21,000,000.00
Related Party Transaction Other Revenues From Transactions With Related Party3,000,000.00
Operating Income1,388.00
Net Income563.00
Earnings Per Share Basic And Diluted-1.68
Earnings Per Share Diluted-1.68
Earnings Per Share Basic-1.68
Cash Flow Statement (mra) ($M)
Cash From Operations1,231.00
Cash from Investing-3,381.00
Cash from Financing-3,381.00
Identifiers and Descriptors
CUSIP16411Q101
Central Index Key (CIK)3570
Related CUSIPS
16411Q901 16411Q951

Split History

Stock splits are used by Cheniere Energy Partners, LP to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

33m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Natural Gas Falls Despite Bullish Inventory Data: Here's Why

16h zacks
The U.S. Energy Department's weekly inventory release showed a smaller-than-expected increase in natural gas supplies. Despite the headline beat, bearish weather predictions pointed to weakening demand and pressured the fuel’s price, which lost around 4% for the week. (43-0)

MLPs Green With Anticipation

2018-07-15 seekingalpha
Midstream had a decent week, highlighted by the MLP Index outperforming U.S. and Canadian midstream corporations and breaking back into positive total return territory year to date. MLPs traded up despite weakness in commodity prices and in utilities. On Monday, in particular, MLP action was encouraging when the UTY was drubbed for a 3% loss and the MLP Index was positive. (2-0)

Global Energy Advisory - 13th July, 2018

2018-07-13 oilprice
U.S. LNG producers are racing to add production capacity amid forecasts for strong growth in demand, with the total—concentrated in Louisiana and Texas—set to reach 10 billion cubic feet daily by the end of next year, from about 4 billion cubic feet a day today. And yet, all this capacity will not be enough to prevent the supply crunch that has been predicted by Shell. (2-0)

Oil Retraces On Libyan Production Surge

2018-07-13 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com. (8-0)

Ferrellgas (FGP) Acquires Diamond Propane, Expands Operations

2018-07-13 zacks
Ferrellgas Partners L.P. (FGP - Free Report) announced the buyout of Diamond Propane, Inc, based in Potsdam, NY. Diamond Propane is a propane retailer that serves residential, agricultural, industrial and commercial customers in and around St. Lawrence County. The acquisition is expected to be immediately accretive to earnings and expand Ferrellgas’ operation in northern New York. Expansion via Acquisition Along with organic growth, Ferrellgas looks for strategic acquisitions of other propane operators to expand footprint across the United States. (11-0)

CUSIP: 16411Q101